Novo Nordisk US Research & Development, Inc.
$7.8K 3 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
OWP Pharmaceuticals, Inc.
OWP Pharmaceuticals, Inc. reported $7,780.60 across General Payments, Research, and Ownership to 412 physicians and teaching hospitals across 412 transactions.
- $7.8K Below-median payer
- All-tracks total
- 412 Above-median volume
- Transactions
- 412 Above-median reach
- Recipients
- −$696.59
- General Payments vs PY2023
OWP Pharmaceuticals, Inc. reported $7,780.60 across all CMS Open Payments tracks (General + Research + Ownership) to 412 physicians and teaching hospitals in Program Year 2024 - ranking #1662 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $7,780.60, averaging $18.88 per recipient.
OWP Pharmaceuticals, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
12/100
Total payments
F
10/100
Transaction volume
F
13/100
Physician reach
F
13/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer owp-pharmaceuticals-inc OWP Pharmaceuticals, Inc.
$7.8K · #1662/1,925 · 0.0% industry · PY2024
- TOT $7.8K
- RANK #1662
- SHARE 0.0%
- TXN 412
- RCP 412
- CAT 1
- GEN $7.8K
- ΔGEN −$696.59
- TOP1 1.1%
- PY 2024
Volume peers
Nearest volume peer: Novo Nordisk US Research & Development, Inc. ($7.8K)
OWP Pharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
OWP Pharmaceuticals, Inc.'s CMS-reported General Payments decreased by $696.59 (−8.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: OWP PHARMACEUTICALS, INC.PY2023: OWP PHARMACEUTICALS, INC.PY2024: OWP Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $8,477.19
- PY2024
- $7,780.60
What the Data Shows for OWP Pharmaceuticals, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For OWP Pharmaceuticals, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
The 1-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Food and Beverage" at $7.8K, accounting for 100.0% of this company's General Payments and 412 transactions.
General Payment Breakdown by Type
OWP Pharmaceuticals, Inc. made 1 types of general payments. "Food and Beverage" is the largest category at $7.8K, 100.0% of General Payments.
How OWP Pharmaceuticals, Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $7.8K | 412 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $384.31 (4.9%) of $7,780.60 in this company's General Payments records across 354 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for OWP Pharmaceuticals, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Lameck Symekah NP
$84.49 across 4 reported transactions
- 2
Eunice Ontita APRN
$84.49 across 4 reported transactions
- 3
Assumpta U Nwagwu Np
$72.87 across 3 reported transactions
- 4
Diana C Manjarres MD
$72.87 across 3 reported transactions
- 5
Tamara O'nan
$69.59 across 4 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
OWP Pharmaceuticals, Inc.'s spend rank (#1662 of 1,925, bottom 14% by spend) and concentration rank (#1,787 of 1,838, bottom 3% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Ethicon US, LLC : $1.6M total payments, HHI 41
- Pylant Medical : $104.7K total payments, HHI 40
- Teva Pharmaceuticals USA, Inc. : $13.9M total payments, HHI 40
- American Orthodontics Corporation : $374.7K total payments, HHI 38
- Impel Pharmaceuticals LLC : $15.8K total payments, HHI 36
- Ultradent Products Inc : $1.8M total payments, HHI 36
- OWP Pharmaceuticals, Inc. (this company) : $7.8K total payments, HHI 35
- Dilon Technologies, Inc. : $148.5K total payments, HHI 35
- Boehringer Ingelheim Pharmaceuticals, Inc. : $17.9M total payments, HHI 34
- Inspire Medical Systems, Inc. : $3.9M total payments, HHI 34
- Hologic Sales and Service, LLC : $1.2M total payments, HHI 33
- CooperVision Inc. : $2.5M total payments, HHI 33
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as OWP Pharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about OWP Pharmaceuticals, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with OWP Pharmaceuticals, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Quest Medical Imaging, Inc
$7.7K 1 recipients
Compare payment profiles
Next Orthosurgical, Inc
$7.7K 7 recipients
Compare payment profiles
Biedermann Motech, Inc.
$7.7K 18 recipients
Compare payment profiles
Kedrion S.p.A.
$7.7K 0 recipients
Compare payment profiles
MeMed US, Inc.
$7.7K 25 recipients
Compare payment profiles
Put this to use
OWP Pharmaceuticals, Inc. ranks #1662 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just OWP Pharmaceuticals, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.